Clinical trials: Non Alcoholic Fatty Liver
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
- Trial name
- NCT05039450
- Testing
- EFX
- Where
- 49 sites in United States, Mexico and 1 more
- Volunteers
- 213 people
- Sponsor
- Akero Therapeutics, Inc
Non-alcoholic Steatohepatitis, Increased Iron Storage / Disturbed Distribution
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
This is a Phase I/II open-label uncontrolled, prospective study to assess the clinical and biological effects of Deferasirox (ICL 670, Exjade®) in patients with NASH and increased iron storage / distribution of iron on liver…
- Trial name
- DEFINE (NCT01278056)
- Testing
- Exjade
- Where
- 9 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Crolll Gmbh
Nonalcoholic Fatty Liver
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
- Trial name
- NCT03763877
- Testing
- PXL770
- Where
- 15 sites in United States
- Volunteers
- 121 people
- Sponsor
- Poxel SA
Non-Alcoholic Fatty Liver Disease, Liver Diseases
Identification and Characterization of NAFLD in Turkey
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Fatty Liver, Metabolic Syndrome
- Trial name
- NCT05194553
- Where
- Turkey (Türkiye)
- Volunteers
- 450 people
- Sponsor
- Maastricht University
Insulin Resistance, NAFLD
Reversal of Lipid-Induced Insulin Resistance
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have…
- Trial name
- NCT02193295
- Testing
- Caloric Restriction
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
Nonalcoholic Fatty Liver Disease, Obesity
High Fructose Corn Syrup
The purpose of this research study is to learn more about how high fructose corn syrup, a sugar used to sweeten drinks and foods, affects metabolism in obese persons with and without nonalcoholic fatty liver disease.
- Trial name
- Fructose (NCT02018237)
- Testing
- High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypercholesterolemia
Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation
Several controlled interventional studies have shown that there is a close correlation between cholesterol reduction and cardiovascular risk; in fact, reductions in serum levels of total cholesterol and low-density lipoprotein…
- Trial name
- NCT06247137
- Testing
- Dietary Supplement
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Bologna
Liver Diseases
Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a…
- Trial name
- 4D-MRI Liver (NCT05385237)
- Testing
- 4D-MRI
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Non Alcoholic Fatty Liver Disease
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
There is preliminary evidence that Omega 3, a compound naturally found in fish oil, reduces the amount of fat stored in the liver and improves liver function.
- Trial name
- NCT01277237
- Testing
- Omacor, lactose tablet
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Edinburgh
Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM.
- Trial name
- NCT01674972
- Testing
- Oral glucose tolerance test
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
- Trial name
- NAFLD (NCT02077374)
- Testing
- IDN-6556
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- Conatus Pharmaceuticals Inc.
NASH - Nonalcoholic Steatohepatitis
Effect of DMR in the Treatment of NASH
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes.
- Trial name
- DMR_NASH_001 (NCT03536650)
- Testing
- DMR
- Where
- Belgium
- Volunteers
- 14 people
- Sponsor
- Erasme University Hospital
NAFLD
Effect of Consumption of Millet Diet in Patients With NAFLD
With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition.
- Trial name
- NCT06341790
- Testing
- jowar based products
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Nonalcoholic Fatty Liver Disease (NAFLD)
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs.
- Trial name
- NF-NAFLD (NCT02213224)
- Testing
- Perindopril, Telmisartan, Amlodipine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Phenylketonurias, Non Alcoholic Fatty Liver
Walking Program in Fatty Liver Children With Phenylketonuria
phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood.
- Trial name
- NCT06718842
- Testing
- walking free online supervised program
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Glucagon Resistance in Patients With NAFLD
The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Glucose Metabolism Disorders
- Trial name
- NCT04042142
- Testing
- glucagon
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Non Alcholic Fatty Liver Disease, Hepatic Steatosis
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease
- Conditions
- Non Alcholic Fatty Liver Disease, Hepatic Steatosis, Hepatic Fibrosis, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT06739486
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NAFLD, Precision Medicine
The Liver BIoBank Lombardia of Fatty Liver
NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple…
- Conditions
- NAFLD, Precision Medicine, Cardiovascular Diseases
- Trial name
- NCT06566105
- Testing
- precision medicine approach
- Where
- Italy
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-Alcoholic Fatty Liver Disease
Ultrasound Liver Fat Quantification on Pediatric Patients
This prospective study aims to recruit pediatric patients with confirmed or suspected non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatosis hepatitis (NASH) and who are eligible for standard ultrasound and MRI…
- Trial name
- NCT06095479
- Testing
- 2D ultrasound scan and MRI examination
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Philips (China) Investment CO., LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.